Tips for Managing Blood Glucose Levels:
- Stay hydrated by drinking plenty of water throughout the day.
- Aim for a balanced diet rich in whole grains, lean proteins, and healthy fats.
- Incorporate regular physical activity into your routine to help regulate blood sugar levels.
- Get enough sleep to reduce stress and promote overall well-being.
- Monitor your blood glucose levels closely and keep a log to track patterns and make necessary adjustments.
- Avoid sugary drinks and processed foods that can cause spikes in blood sugar levels.
Additional Resources for Diabetes Management:
- Join a support group or online community for people with diabetes to share experiences and tips.
- Consult with a registered dietitian or diabetes educator for personalized guidance on meal planning and blood glucose control.
- Stay up-to-date on the latest research and developments in diabetes management through reputable sources.
- Consider talking to a mental health professional if you are struggling with the emotional impact of living with diabetes.
Essential Tips for Individuals with Type 1 Diabetes
If you have type 1 diabetes, it is imperative to carry rapid-acting glucose sources, educate your loved ones about hypoglycemia, wear medical identification, adapt to various circumstances, monitor blood glucose during physical activity, contemplate continuous glucose monitoring, adhere to sick day protocols, inform medical personnel about your diabetes during emergencies, and manage alcohol consumption.
Leading a Fulfilling Life with Type 1 Diabetes
Planning for Pregnancy with Type 1 Diabetes
Maintaining a healthy pregnancy with type 1 diabetes requires thorough planning and effective blood glucose management. Additional support and monitoring are vital during pregnancy.
Managing type 1 diabetes during pregnancy can be challenging, especially when it comes to insulin accessibility. It is crucial for pregnant women with type 1 diabetes to have access to uninterrupted insulin supply to maintain stable blood glucose levels and ensure the health of both mother and baby.
Insulin accessibility issues, such as cost barriers or supply shortages, can have serious implications for pregnant women with type 1 diabetes. It is essential for healthcare providers and policymakers to address these challenges and ensure that pregnant women with type 1 diabetes have reliable access to insulin throughout their pregnancy.
Importance of Continuous Glucose Monitoring
In addition to ensuring access to insulin, continuous glucose monitoring (CGM) devices play a critical role in managing diabetes effectively. CGM technology provides real-time updates on blood glucose levels, allowing individuals to make informed decisions about insulin dosing and dietary choices. Studies have shown that CGM use can lead to improved glycemic control and reduced risk of complications associated with diabetes.
Educating Healthcare Providers on Insulin Insecurity
It is essential to educate healthcare providers about the challenges faced by individuals with diabetes due to insulin insecurity. By raising awareness about the impact of high insulin costs and rationing, healthcare professionals can better support their patients and advocate for policies that address these issues. Additionally, training programs should emphasize the importance of proactive management strategies to prevent DKA and other complications.
Promoting Affordable Insulin Access
Governments, healthcare organizations, and pharmaceutical companies must work together to promote affordable insulin access for all individuals with diabetes. Initiatives such as price caps, insurance coverage mandates, and patient assistance programs can help alleviate the financial burden of insulin therapy. By prioritizing affordability and accessibility, we can ensure that no one has to endure the dire consequences of insulin insecurity.
It is important for individuals with type 1 diabetes to closely monitor their blood sugar levels, as high levels can contribute to complications such as cardiovascular disease. Additionally, managing lipid disorders through diet, exercise, and medication can help reduce the risk of premature mortality.
Regular screenings for kidney disease are also essential, as the absence of this complication can indicate a better prognosis and increased survival rates. Monitoring for other complications associated with diabetes, such as metabolic syndrome, can help healthcare providers identify individuals who may be at higher risk for premature mortality.
By focusing on early intervention, lifestyle modifications, and regular medical care, individuals with type 1 diabetes can enhance their overall quality of life and improve their chances of living well into old age. It is important for healthcare providers to work closely with patients to develop personalized treatment plans that address their unique needs and risk factors.
Mortality Patterns in Type 1 Diabetes
Prior to the advent of insulin, individuals with type 1 diabetes faced a life expectancy of less than three years. Although survival has increased, those with type 1 diabetes still experience higher mortality rates from cardiovascular issues. Patients with type 1 diabetes reach a ten-year risk of fatal cardiovascular disease before the general population.
Comparison of Heart Disease Mortality in Type 1 Diabetes vs the General Population
Despite advancements in diabetes management, individuals with type 1 diabetes are predisposed to a shorter lifespan due to premature cardiovascular disease. Nevertheless, a subset of patients lives into old age with good health. Identifying and supporting these patients can enhance overall survival rates.
Factors Affecting Longevity in Type 1 Diabetes
Type 1 diabetes is characterized by hyperglycemia resulting from β-cell dysfunction and inadequate insulin production. Prolonged inadequate blood sugar control is linked to increased mortality rates and a higher risk of cardiovascular disease (CVD). Timely glycemic control is vital in preventing cardiovascular issues, as demonstrated by various studies.
The correlation between HbA1c levels and survival has been established. While glycemic control impacts CVD risk and mortality, its significance may decrease with age. Type 1 diabetes patients also commonly experience lipid abnormalities, with HbA1c levels showing a direct relationship with lipid profiles. Elevated LDL and non-HDL cholesterol levels raise CVD risk, whereas higher HDL cholesterol levels can offer protection against CVD and promote longevity. Hypertension, particularly in patients with underlying kidney disease, poses a significant CVD risk factor.
Diabetic nephropathy is a notable risk factor for coronary artery disease (CAD), cardiovascular mortality, and stroke in individuals with type 1 diabetes. Sustained glycemic control plays a vital role in diminishing albumin excretion rates and delaying the onset of complications like hypertension and reduced kidney function.
To conclude, early glycemic control is crucial in averting cardiovascular disease and improving longevity in type 1 diabetes patients. Effective management of lipid levels, blood pressure, and kidney health is imperative for reducing CVD risk and enhancing outcomes.
| Death from any cause | Deaths from heart-related issues | Ischemic heart disease | |
| High Creatinine Levels | 5.1 | 6.29 | 4.25 |
| Microalbuminuria | 1.32 | 1.44 | 1.40 |
| High levels of albumin in urine | 2.4 | 2.57 | 1.77 |
The medical term IHD stands for Ischaemic heart disease.
In individuals with type 1 diabetes, the highest occurrence of nephropathy typically occurs 15 to 20 years after the onset of diabetes. The progression to noticeable neuropathy diminishes over time. Individuals with long-standing diabetes usually remain free from nephropathy.
There is no significant correlation between retinopathy and CVD or mortality in type 1 diabetes patients. Severe diabetic retinopathy is prevalent. It appears that retinopathy does not pose a significant risk for CVD or mortality in individuals with type 1 diabetes.
There is no conclusive link between neuropathy and CAD or mortality, with the exception of specific research findings.
TYPE 1 DIABETES AND THE METABOLIC SYNDROME
Individuals with type 1 diabetes may have a similar prevalence of MetS as the general population. MetS in these individuals is associated with an elevated risk of macrovascular disease and mortality.
Recognizing the characteristics of MetS in type 1 diabetes can be difficult. Factors such as hypertension should not be overlooked due to their implications for nephropathy. Estimating insulin resistance may involve using proxies such as insulin dosage.
A higher risk of IMT is linked to the number of MetS features present in individuals with type 1 diabetes, indicating overall stiffness of the arterial walls.
Figure 3.
A notable increase in Intima-Media Thickness is evident in individuals with MetS.
GENETIC FACTORS
Genetic factors play a role in the longevity of individuals with type 1 diabetes. A family history of type 2 diabetes or hypertension can lead to increased IMT in these individuals.
Multiple risk factors interact to determine outcomes in individuals with type 1 diabetes. Identifying specific factors clinically can be crucial.
Figure 4.
Complex relationships exist between multiple risk factors in individuals with type 1 diabetes. CVD refers to Cardiovascular disease.
Table 2.
Characteristics of individuals with long-standing type 1 diabetes:
| Maintaining glycaemic control at a reasonable level (not necessarily perfect) |
| Having elevated levels of HDL-cholesterol |
| Requiring low amounts of insulin daily (being “insulin sensitive”) |
| Maintaining normal body weight |
| Being a non-smoker |
| Having lower blood pressure readings |
| Testing negative for microalbuminuria after 15-20 years of diabetes |
| Having a family history of living a long life |
HDL: High-density lipoprotein.
CONCLUSION
Although type 1 diabetes patients are experiencing longer lifespans, their life expectancy still falls short of that of non-diabetic individuals. The longevity of type 1 diabetes patients heavily depends on modifiable risk factors.
It is crucial for individuals with type 1 diabetes to manage their blood sugar levels effectively through insulin therapy, proper diet, regular exercise, and regular check-ups with healthcare providers. Additionally, avoiding smoking, managing stress, and maintaining a healthy weight can also play a significant role in improving the longevity and quality of life for type 1 diabetes patients.
Educating patients on the importance of self-care and empowering them to take control of their health can lead to better outcomes and a longer, healthier life for individuals living with type 1 diabetes. By making positive lifestyle choices and staying vigilant about managing their condition, type 1 diabetes patients can increase their life expectancy and reduce the risk of complications associated with the disease.
ACKNOWLEDGMENTS
A special acknowledgment goes to Michael Brown for his valuable help in editing and preparing this manuscript.
Footnotes
P – Reviewers: Masuo K, PIzawa K S – Editor: Song XX L – Editor: A E – Editor: Liu SQ
References
- For more information on the historical aspects of type 1 diabetes, visit: Diapedia.
- Study on cause-specific mortality in a population-based diabetes study. Am J Public Health. 1991;81:1158–1162.
- Research indicating a high risk of cardiovascular disease in UK patients with type 1 diabetes: Diabetes Care. 2006;29:798–804.
Articles from the World Journal of Diabetes are shared here courtesy of Baishideng Publishing Group Inc.
1. Soedamah-Muthu SS, Chaturvedi N, Toeller M, Ferriss B, Reboldi P, Michel G, Manes C, Fuller JH. Risk factors for coronary heart disease in type 1 diabetic patients in Europe: the EURODIAB Prospective Complications Study. Diabetes Care. 2004;27:530–537.
2. Sundquist K, Li X. Type 1 diabetes as a risk factor for stroke in men and women aged 15-49: a nationwide study from Sweden. Diabet Med. 2006;23:1261–1267.
3. Grauslund J, Jørgensen TM, Nybo M, Green A, Rasmussen LM, Sjølie AK. Risk factors for mortality and ischemic heart disease in patients with long-term type 1 diabetes. J Diabetes Complications. 2010;24:223–228.
4. Nathan DM, Cleary PA, Backlund JY, Genuth SM, Lachin JM, Orchard TJ, Raskin P, Zinman B. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med. 2005;353:2643–2653.
5. Nathan DM, Lachin J, Cleary P, Orchard T, Brillon DJ, Backlund JY, O’Leary DH, Genuth S. Intensive diabetes therapy and carotid intima-media thickness in type 1 diabetes mellitus. N Engl J Med. 2003;348:2294–2303.
6. Bain SC, Gill GV, Dyer PH, Jones AF, Murphy M, Jones KE, Smyth C, Barnett AH. Characteristics of Type 1 diabetes of over 50 years duration (the Golden Years Cohort) Diabet Med. 2003;20:808–811.
7. Larsen J, Brekke M, Sandvik L, Arnesen H, Hanssen KF, Dahl-Jorgensen K. Silent coronary atheromatosis in type 1 diabetic patients and its relation to long-term glycemic control. Diabetes. 2002;51:2637–2641.
8. Mäkimattila S, Ylitalo K, Schlenzka A, Taskinen MR, Summanen P, Syvänne M, Yki-Järvinen H. Family histories of Type II diabetes and hypertension predict intima-media thickness in patients with Type I diabetes. Diabetologia. 2002;45:711–718.
9. Distiller LA, Joffe BI, Melville V, Welman T, Distiller GB. Carotid artery intima-media complex thickening in patients with relatively long-surviving type 1 diabetes mellitus. J Diabetes Complications. 2006;20:280–284.
10. Selvin E, Marinopoulos S, Berkenblit G, Rami T, Brancati FL, Powe NR, Golden SH. Meta-analysis: glycosylated hemoglobin and cardiovascular disease in diabetes mellitus. Ann Intern Med. 2004;141:421–431.
11. Marcovecchio ML, Dalton RN, Prevost AT, Acerini CL, Barrett TG, Cooper JD, Edge J, Neil A, Shield J, Widmer B, et al. Prevalence of abnormal lipid profiles and the relationship with the development of microalbuminuria in adolescents with type 1 diabetes. Diabetes Care. 2009;32:658–663.
12. Guy J, Ogden L, Wadwa RP, Hamman RF, Mayer-Davis EJ, Liese AD, D’Agostino R, Marcovina S, Dabelea D. Lipid and lipoprotein profiles in youth with and without type 1 diabetes: the SEARCH for Diabetes in Youth case-control study. Diabetes Care. 2009;32:416–420.
13. Nikkilä EA, Huttunen JK, Ehnholm C. Postheparin plasma lipoprotein lipase and hepatic lipase in diabetes mellitus. Relationship to plasma triglyceride metabolism. Diabetes. 1977;26:11–21.
14. Taskinen MR. Quantitative and qualitative lipoprotein abnormalities in diabetes mellitus. Diabetes. 1992;41 Suppl 2:12–17.
15. Dabelea D, Talton JW, D’Agostino R, Wadwa RP, Urbina EM, Dolan LM, Daniels SR, Marcovina SM, Hamman RF. Cardiovascular risk factors are associated with increased arterial stiffness in youth with type 1 diabetes: the SEARCH CVD study. Diabetes Care. 2013;36:3938–3943.
16. Soedamah-Muthu SS, Chaturvedi N, Witte DR, Stevens LK, Porta M, Fuller JH. Relationship between risk factors and mortality in type 1 diabetic patients in Europe: the EURODIAB Prospective Complications Study (PCS) Diabetes Care. 2008;31:1360–1366.
17. Molitch ME, Rupp D, Carnethon M. Higher levels of HDL cholesterol are associated with a decreased likelihood of albuminuria in patients with long-standing type 1 diabetes. Diabetes Care. 2006;29:78–82.
18. Hägg S, Thorn LM, Putaala J, Liebkind R, Harjutsalo V, Forsblom CM, Gordin D, Tatlisumak T, Groop P-H; on behalf of the FinnDiane Study Group. Incidence of Stroke According to Presence of Diabetic Nephropathy and Severe Diabetic Retinopathy in Patients With Type 1 Diabetes. American Diabetes Association. 2013;36:4140–4146.
19. Writing Team for the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group. Sustained effect of intensive treatment of type 1 diabetes mellitus on the development and progression of diabetic nephropathy: the Epidemiology of Diabetes Interventions and Complications (EDIC) study. JAMA. 2003;290:2159–2167.
20. de Boer IH, Sun W, Cleary PA, Lachin JM, Molitch ME, Steffes MW, Zinman B. Intensive diabetes therapy and glomerular filtration rate in type 1 diabetes. N Engl J Med. 2011;365:2366–2376.
21. Rossing P, Hougaard P, Parving HH. Progression of microalbuminuria in type 1 diabetes: ten-year prospective observational study. Kidney Int. 2005;68:1446–1450.
22. Rossing P. Prediction, progression, and prevention of diabetic nephropathy. The Minkowski Lecture 2005. Diabetologia. 2006;49:11–19.
23. Liew G, Wong TY, Mitchell P, Cheung N, Wang JJ. Retinopathy predicts coronary heart disease mortality. Heart. 2009;95:391–394.
24. Studies to Treat or Prevent Pediatric Type 2 Diabetes Prevention Study Group. Prevalence of the metabolic syndrome among a racially/ethnically diverse group of U.S. eighth-grade adolescents and associations with fasting insulin and homeostasis model assessment of insulin resistance levels. Diabetes Care. 2008;31:2020–2025.
25. Ghosh S, Collier A, Hair M, Malik I, Elhadd T. MetS in type 1 diabetes. Int J Diabetes Mellitus. 2010;2:38–42.
26. Cleland SJ, Fisher BM, Colhoun HM, Sattar N, Petrie JR. Insulin resistance in type 1 diabetes: what is ‘double diabetes’ and what are the risks? Diabetologia. 2013;56:1462–1470.
27. Williams KV, Erbey JR, Becker D, Arslanian S, Orchard TJ. Can clinical factors estimate insulin resistance in type 1 diabetes? Diabetes. 2000;49:626–632.
28. Distiller LA, Joffe BI, Brown V, Distiller GB. The effect of features of the metabolic syndrome on atherosclerotic risk in relatively long-surviving patients with type 1 diabetes. Metab Syndr Relat Disord. 2010;8:539–543.